Wadlinger Mary E. 4
4 · Forma Therapeutics Holdings, Inc., · Filed Jun 24, 2020
Insider Transaction Report
Form 4
Wadlinger Mary E.
See Remarks
Transactions
- Sale
Enterprise 2 Junior Stock
2020-06-23−91,876→ 0 total - Sale
Enterprise 3 Junior Stock
2020-06-23−23,354→ 0 total - Purchase
Common Stock
2020-06-23+115,575→ 115,575 total - Sale
Enterprise 4 Junior Stock
2020-06-23−29,222→ 0 total
Footnotes (1)
- [F1]Effective immediately upon the closing of the Registrant's initial public offering on June 23, 2020, the reporting person converted (i) 91,876 shares of Enterprise 2 Junior Stock at a conversion rate of 0.8179 shares of common stock per one share of Enterprise 2 Junior Stock, (ii) 23,354 shares of Enterprise 3 Junior Stock at a conversion rate of 0.7822 shares of common stock per one share of Enterprise 3 Junior Stock and (iii) 29,222 shares of Enterprise 4 Junior Stock at a conversion rate of 0.7585 shares of common stock per one share of Enterprise 4 Junior Stock, resulting in her acquisition of 115,575 shares of common stock.